A multicentre comparison between Child Pugh and Albumin‐Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma


Edeline, J, Blanc, J-F, Johnson, P ORCID: 0000-0003-1404-0209, Campillo-Gimenez, B, Ross, P, Ma, YT, King, J, Hubner, RA, Sumpter, K, Darby, S et al (show 8 more authors) (2016) A multicentre comparison between Child Pugh and Albumin‐Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma Liver international : official journal of the International Association for the Study of the Liver, 36 (12). pp. 1821-1828. ISSN 1478-3223, 1478-3231

[thumbnail of ALBI Child HCC sorafenib Liver Int Revision Final.docx] Text
ALBI Child HCC sorafenib Liver Int Revision Final.docx - Author Accepted Manuscript
Download (60kB)

Abstract

The Albumin-Bilirubin (ALBI) grade was proposed as an objective means to evaluate liver function in patients with Hepatocellular Carcinoma (HCC). ALBI grade 1 vs 2 were proposed as stratification factors within the Child Pugh (CP) A class. However, the original publication did not provide comparison with the subclassification by points (5-15) within the CP classification.We retrospectively analysed data from patients treated with sorafenib for HCC from 17 centres in United Kingdom and France. Overall survival (OS) was analysed using the Kaplan-Meier method and a Cox regression model. Discriminatory abilities of the classifications were assessed with the log likelihood ratio, Harrell's C statistics and Akaike information criterion.Data from 1019 patients were collected, of which 905 could be assessed for both scores. 92% of ALBI grade 1 were CP A5 while ALBI 2 included a broad range of CP scores of which 44% were CP A6. Median OS was 10.2, 7.0 and 3.6 months for CP scores A5, A6 and >A6, respectively (P < 0.001), Hazard Ratio (HR) = 1.60 (95%CI: 1.35-1.89, P < 0.001) for A6 vs A5. Median OS was 10.9, 6.6 and 3.0 months for ALBI grade 1, 2 and 3, respectively (P < 0.001), HR = 1.68 (1.43-1.97, P < 0.001) for grade 2 vs 1. Discriminatory abilities of CP and ALBI were similar in the CP A population, but better for CP in the overall population.Our findings support the use CP class A as an inclusion criterion, and ALBI as a stratification factor in trials of systemic therapy.

Item Type: Article
Uncontrolled Keywords: Albumin, bilirubin, cirrhosis, liver function, prognosis
Depositing User: Symplectic Admin
Date Deposited: 17 Jan 2017 08:52
Last Modified: 24 Jun 2026 12:53
DOI: 10.1111/liv.13170
Related Websites:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3002919
Disclaimer: The University of Liverpool is not responsible for content contained on other websites from links within repository metadata. Please contact us if you notice anything that appears incorrect or inappropriate.
Altmetric
CORE (COnnecting REpositories)